Effects of a Multi-Pathway Dietary Supplement (Stem Cell 100+) on Indices of Health and Life Expectancy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Heart Rate
研究概览
简要总结
This open-label field trial evaluates the effects of treatment with a multi-pathway dietary supplement (Stem Cell 100+) that has been commercially available for several years. The objective of the intervention trial is to determine if normal subjects over 35 years of age experience any observable health benefits from the dietary supplement as to their blood pressure, pulse rate, blood cholesterol, lung capacity, stress levels, or self reported changes in markers of overall health and life expectancy.
详细描述
Currently, only dietary restriction has been verified to slow the rate of aging and to promote general health. This trial is designed to see whether a complex supplement (Stem Cell 100+) that targets multiple longevity pathways could also have positive effects on several markers of successful aging and good health. Multipath causes of aging include: stem cell function, telomere loss, chronic stress, inflammation, insulin-like growth factors, autophagy, vascular loss, neural dysfunction, and oxidative stress. The goal of the study was to test the effects of this novel multipath intervention strategy in a clinical trial of healthy people using health markers such as blood pressure, cholesterol status, lung function, stress levels, and self-reported health status. Hundreds of published animal and human clinical studies have been done with each of the individual active ingredients in the formulation, which target many critical causes of aging.
Based on their published animal studies showing extension of life span in a model animal and their laboratory work on adult human stem cells, the investigators believe that Stem Cell 100+ will provide evidence of efficacy in addressing multiple index markers of health and life expectancy outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No history of serious cardiovascular, cancer, or neural disease.
- •Normal health for age
- •Willing to have blood drawn at baseline and after trial
- •Willing to submit to evaluation testing of blood pressure, lung testing, stress testing.
- •Willing to take online self reported survey of health at end of trial
排除标准
- •History of metastatic cancer, heart attack, dementia, or other life-threatening disease
- •Any subject who is not capable of responding to a self-reported online questionnaire
结局指标
主要结局
Heart Rate
时间窗: Baseline and at an average of 15 weeks
Change in Heart Rate
HDL Cholesterol
时间窗: Baseline and at an average of 15 weeks
Change in HDL Cholesterol
Stress Level
时间窗: Baseline and at an average of 15 weeks
Change in Heart Rate Variability
Blood Pressure
时间窗: Baseline and at an average of 15 weeks
Change in Systolic and Diastolic Blood Pressure
Lung Capacity
时间窗: Baseline and at an average of 15 weeks
Change in Peak Expiatory Flow
次要结局
- Vitality(From baseline through study completion, an average of 15 weeks)
- Ability to Concentrate or Focus(From baseline through study completion, an average of 15 weeks)
- Joint Flexibility(From baseline through study completion, an average of 15 weeks)
- Ability to Relax(From baseline through study completion, an average of 15 weeks)
- Stress Tolerance(From baseline through study completion, an average of 15 weeks)
- Ease of Walking(From baseline through study completion, an average of 15 weeks)
- Climbing Stairs(From baseline through study completion, an average of 15 weeks)
- Overall Mood(From baseline through study completion, an average of 15 weeks)
- Overall Health(From baseline through study completion, an average of 15 weeks)
- Cold/Flu Resistance(From baseline through study completion, an average of 15 weeks)
- Work Productivity(From baseline through study completion, an average of 15 weeks)
- Energy Level(From baseline through study completion, an average of 15 weeks)
- Endurance(From baseline through study completion, an average of 15 weeks)